Physician profile
Christopher Ryan Papp
NPI 1669493342
$1,119.37
in general payments reported to CMS, 2019-2025
19 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.89 · 2020: $69.50 · 2021: $118 · 2022: $361 · 2023: $204 · 2024: $151 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461 · Entertainment: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.29 |
| Entertainment | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $174.62 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $118.55 | 2019-2022 | |
| Rxsight INC | $111.05 | 2022 | |
| Bausch & Lomb Americas INC. | $99.73 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Genentech USA, INC. | $91.53 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $78.58 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $62.76 | 2019-2020 | |
| Alcon Vision LLC | $53.97 | 2023-2025 | Argos, Clareon, Rocklatan |
| Optos, INC. | $52.00 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $45.20 | 2023-2024 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $43.70 | 2022-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Sun Pharmaceutical Industries INC. | $41.01 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $32.73 | 2023 | Eylea Hd |
| Kala Pharmaceuticals, INC. | $23.92 | 2021 | |
| Dompe US, INC. | $21.65 | 2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $19.95 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $18.03 | 2021 | |
| Abbvie INC. | $15.36 | 2022 | |
| Spark Therapeutics, INC. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Papp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.